Edap Tms S.A. (EDAP)
NASDAQ:EDAP
EDAP Stock Chart & Stats
$3.32
-$0.15(-5.88%)
At close: 4:00 PM EST
$3.32
-$0.15(-5.88%)
Day’s Range― - ―
52-Week Range$1.21 - $5.05
Previous CloseN/A
Volume29.75K
Average Volume (3M)36.79K
Market Cap
$123.69M
Enterprise Value$117.37M
Total Cash (Recent Filing)$17.41M
Total Debt (Recent Filing)$27.68M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 20, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding37,481,987
10 Day Avg. Volume26,597
30 Day Avg. Volume36,789
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)6.35
Price to Sales (P/S)1.74
P/FCF Ratio-6.55
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue1.80
Enterprise Value/Gross Profit3.90
Enterprise Value/Ebitda-5.39
Forecast
1Y Price Target
$6.25Price Target Upside88.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$65.45M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionRecord placements of the Focal One HIFU system and standardization across major health systems support accelerating commercial adoption and higher procedure volumes.
Reimbursement PolicyHigher Medicare reimbursement for the Focal One procedure creates a clearer financial incentive for hospitals and physicians to adopt the technology and boost utilization.
Revenue GuidanceManagement issued revenue guidance above market consensus, signaling confidence in continued topline expansion driven by the HIFU business.
Bears Say
Currency VolatilityCurrency fluctuations present a risk to reported revenue and earnings for the company given its international exposure.
Margin PressureGross margin faces pressure from tariffs and an inventory reserve related to legacy parts, which could weigh on near-term profitability.
Regulatory And Intellectual Property RiskRegulatory hurdles and potential intellectual property disputes could delay commercialization in key markets or increase legal and compliance costs.
EDAP TMS News
EDAP FAQ
What was Edap Tms S.A.’s price range in the past 12 months?
Edap Tms S.A. lowest stock price was $1.21 and its highest was $5.05 in the past 12 months.
What is Edap Tms S.A.’s market cap?
Edap Tms S.A.’s market cap is $123.69M.
When is Edap Tms S.A.’s upcoming earnings report date?
Edap Tms S.A.’s upcoming earnings report date is May 20, 2026 which is in 35 days.
How were Edap Tms S.A.’s earnings last quarter?
Edap Tms S.A. released its earnings results on Mar 25, 2026. The company reported -$0.259 earnings per share for the quarter, missing the consensus estimate of -$0.151 by -$0.108.
Is Edap Tms S.A. overvalued?
According to Wall Street analysts Edap Tms S.A.’s price is currently Undervalued.
Does Edap Tms S.A. pay dividends?
Edap Tms S.A. does not currently pay dividends.
What is Edap Tms S.A.’s EPS estimate?
Edap Tms S.A.’s EPS estimate is -0.21.
How many shares outstanding does Edap Tms S.A. have?
Edap Tms S.A. has 37,481,987 shares outstanding.
What happened to Edap Tms S.A.’s price movement after its last earnings report?
Edap Tms S.A. reported an EPS of -$0.259 in its last earnings report, missing expectations of -$0.151. Following the earnings report the stock price went down -5.115%.
Which hedge fund is a major shareholder of Edap Tms S.A.?
Currently, no hedge funds are holding shares in EDAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EDAP TMS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.25 (88.25% Upside)
$6.25 (88.25% Upside)
Blogger Sentiment
Bullish
EDAP Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-111.74%
Trailing 12-Months
Asset Growth
-11.36%
Trailing 12-Months
Company Description
Edap Tms S.A.
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
EDAP Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a strong and accelerating commercial performance in the core Focal One HIFU business—record placements, double-digit procedure growth, expanded academic penetration, regulatory clearance, favorable reimbursement, clear international expansion and confident 2026 guidance. These positive operational and market developments are tempered by company-level challenges: total revenue declined modestly due to legacy noncore segment contraction, gross margin compression from tariffs and inventory reserves, increased operating and net losses driven by noncash charges, interest and currency effects, and ongoing seasonality/lumpiness of capital sales. Overall, the momentum in the high-margin HIFU franchise and reiterated growth guidance outweigh the near-term financial headwinds, supporting a constructive outlook as the company transitions toward being evaluated more on HIFU metrics.View all EDAP earnings summariesEDAP Stock 12 Month Forecast
Average Price Target
$6.25
▲(88.25% Upside)